Clinical trial to evaluate combination regimen of  recombinant human interleukin-7to treat metastatic breast cancer

26 May 2011

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard (Lyon), the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS (Grenoble), a diagnostic company specialized in innovative immunomonitoring tests and services, have announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7 (CYT107), the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA (R) (capecitabine, Roche/Genentech), in the treatment of metastatic breast cancer.  
The trial is designed to explore the optimal schedule for delivery of CYT107 during standard capecitabine chemotherapy, with the aim of immune reconstitution and collection of preliminary data on the impact of CYT107 on severe hematological toxicity and tumor progression in second line metastatic breast cancer patients. The immunorestorative properties of IL‑7, which include its ability to provide T cells to attack any residual disease, are expected to have a significant impact on survival in this patient population, where a low CD4 T cell count associated with poor receptor diversity detected before initiation of chemotherapy is a known predictive factor indicating overall survival of less than six months compared to almost two years for non-lymphopenic patients.
Conducted as a collaborative effort of the Centre Léon Bérard (the study sponsor), ImmunID Technologies, and Cytheris, the study, known as ELYPSE-7, is designed to evaluate whether CYT107 treatment is able to correct lymphopenia post-chemotherapy in advanced cancer patients and whether the correction of this lymphopenia by restoration of the immune system will result in a broadening of the repertoire of T cells and a reduction in the risk of severe haematological toxicity, tumor progression and early death.
The study is based on many years of research conducted by the team of Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, and the current president of the European Organization for Research and Treatment of Cancer (EORTC).

Lymphopenia (<1000 Lymphocytes/microliters) or CD4+ T cell lymphopenia (<450/microliters) detected prior to initiation of chemotherapy as well as Divpenia (R) (low diversity of the T cell repertoire) are known to be predictive factors for toxicity and death in patients with metastatic solid tumors. Correction of this condition through an immunotherapeutic approach would therefore represent a potential paradigm shift in the treatment of patients with various types of cancer,” commented Dr. Blay. “In the SEMTOF trial, which included a total of 70 metastatic breast cancer patients in first line treatment, a low T cell receptor (TCR) repertoire diversity (Divpenia (R), as defined and measured by ImmunID Technologies) was associated with a short overall survival of up to six months. Median survival of severely divpenic patients was less than six months, compared to  more than 22 months for the remaining patients who were not in this severely lymphopenic state. The outcome of the ELYPSE-7 study is thus expected to have significant implications for overall survival and tumor progression in patients with advanced cancers, including ovarian cancer, metastatic breast cancer, non-Hodgkin lymphoma, and sarcoma.”
Qualitative and quantitative alterations of local and circulating immune cells have been identified as playing an important role in breast cancer progression. In a series of studies including more than 3000 patients, Dr. Blay’s team has shown that lymphopenia is found in 20-25 per cent of patients with advanced cancers, including 20 per cent of untreated patients with metastatic breast cancer. In a large series of patients it was observed that lymphopenia is associated with a 20 per cent and 50 per cent risk of early death at one and three months and that T cell CD4 lymphopenia is also an independent risk factor for early death and toxicity in these patients.
“In a recent review article (Mackall C et al. Nat Rev Immunol. 2011 May; 11(5):330-42) entitled “Harnessing the Biology of IL-7 for Therapeutic Application”, the authors conclude that despite the impressive biological effects of IL-7 on T cell populations, the essential issue regarding clinical development of this cytokine is the need to show that the biological effects of IL‑7 translate to improved clinical outcomes such as prolonged survival or cure,” said Michel Morre, DVM, president and CEO of Cytheris. “Such proof of concept can only be obtained by carrying out careful clinical trials in targeted populations who are at greatest risk owing to T cell immunodeficiency, precisely the goal of the ELYPSE-7 study.”

About the Study
ELYPSE-7 is a randomised, monocentric, double-blind Phase IIa study evaluating the impact of IL-7 immunotherapy on CD4 lymphopenia and TCR repertoire diversity, risks of severe haematological toxicity and tumor progression in metastatic breast cancer patients. Twenty-four patients will be enrolled at a single center (Centre Léon Bérard, Lyon, France) where the study is under the direction of Isabelle Ray-Coquard, MD, PhD, principal investigator.

The duration of the investigation for each patient will include a study drug treatment period of at least 12 weeks (including three x three-week cycles of chemotherapy) and a follow-up period for a maximum of one year (or until disease progression). Chemotherapy will be extended until disease progression, unacceptable toxicity, or willingness to stop. The inclusion period is expected to be six months with the treatment period and follow-up lasting up to one year.

All patients will receive standard anti-cancer therapy prescribed for second line metastatic breast cancer patients: XELODA (R) (capecitabine) at an oral dose of 2500mg/day for 14 days over a 21-day cycle period. In addition, all patients will be randomly allocated in a factorial design to one of the following four study arms:

  • Arm one: (Placebo Group) Patients will receive Placebo before the start of chemotherapy (at D0, D7 and D14) and during the third cycle of chemotherapy (D63, D70 and D77).
  • Arm two: (Pre-IL-7 Treatment Group) Patients will receive CYT107 (one subcutaneous injection at ten micrograms/kg/week for three weeks) before the first cycle of chemotherapy (at D0, D7 and D14) and will receive the placebo during the third cycle of chemotherapy (D63, D70 and D77).
  • Arm three: (Concomitant IL-7 Treatment Group) Patients will receive Placebo before the first cycle of chemotherapy (D0, D7 and D14) and will receive CYT107 (one subcutaneous injection at ten micrograms/kg/week for three weeks) during the third cycle of chemotherapy (at D63, D70 and D77).
  • Arm four: (Pre- and Concomitant IL-7 Treatment) Patients will receive CYT107 (one subcutaneous injection at ten micrograms/kg/week for three weeks) before the first cycle of chemotherapy (D0, D7 and D14) and again (one subcutaneous injection at ten micrograms/kg/week for three weeks) during the third cycle of chemotherapy (D63, D70 and D77).

The primary endpoint of the study is the evolution of patient CD4 counts from D0 to W12 with repeated measures at D0, W3, W9, and W12. This will help in defining the optimal schedule of CYT107 administration during chemotherapy, based on the restoration of patient CD4 counts.

Secondary endpoints include the impact of CYT107 treatment on the incidence of severe hematological toxicity as indicated by the number of patients experiencing any type of hematological Adverse Event (including anemia, thrombopenia, lymphopenia, or neutropenia) of Grade ≥ three from D0 to W12. At this stage, the quality of T cell repertoire diversity reconstitution will also be assessed.

About Recombinant Human Interleukin-7 (CYT107)

Recombinant human interleukin-7 (CYT107) is a critical immune-modulator for immune T-cell recovery and enhancement. As a growth factor and cytokine physiologically produced by marrow or thymic stromal cells and other epithelia, IL-7 has a critical and, at some steps, a non-redundant stimulating effect on T lymphocyte development, notably on thymopoiesis and, downstream from the thymus, on homeostatic expansion of peripheral T-cells.

Clinical trials including more than 180 patients in Europe, North America, South Africa and Taiwan have demonstrated the potential of IL-7 to expand and protect CD4 and CD8 T-cells. Currently, Cytheris is conducting multiple international investigations of IL-7 in HIV, HCV, HBV, post-BMT and cancer. Additional studies include a NIAID/NIH-sponsored trial (ICICLE) in idiopathic CD4 lymphocytopenia (ICL); a cancer vaccine study in children with Ewing's sarcoma family of tumors or similar genetic tumors sponsored by US National Cancer Institute; and, a multi-company/institutional study (EraMune 01) sponsored by ORVACS (the international HIV organization funded by the French Bettencourt Schueller Foundation) aimed at attacking the HIV viral reservoir.

Source: Cytheris

To top